# GSK catches phase 3 fever after mRNA flu vaccine beats standard shots

> **Open Intelligence Dossier** · First detected: 2026-09-01 20:07 UTC · Category: Business

## Executive Summary
GSK advances its mRNA flu vaccine candidate to phase 3 trials following successful mid-stage performance data.

## Intelligence Brief
GSK is actively pushing its next-generation, dual-target mRNA flu vaccine candidate into a late-stage Phase 3 trial. This strategic progression comes after the vaccine candidate demonstrated positive Phase 2 data where it reportedly beat standard vaccines in a mid-stage trial. Additionally, coverage notes that mFlusiva has become the first mRNA influenza vaccine approved by the Food and Drug Administration. The reporting places heavy emphasis on the broader resurgence of the mRNA modality within the pharmaceutical sector.


Publications such as 24/7 Wall St. and finance.biggo.com have highlighted market reactions, noting that Moderna rose six percent despite GSK moving its rival mRNA flu candidate forward. Meanwhile, local and regional outlets like AL.com, Yahoo, and Connecticut Public have directed attention toward practical public health considerations, discussing big changes for this year's flu shot, optimal timing for vaccinations, and how new formulations might offer better protection for older adults. Financial analysis and commentary platforms, including Seeking Alpha, continue to position GSK as a top healthcare pick amidst these clinical milestones. This movement into late-stage testing arrives against a backdrop of renewed industry focus on messenger RNA technology beyond traditional applications.


While the coverage outlines the transition from mid-stage success to the launch of Phase 3 testing with a newer formulation, specific details regarding trial locations, exact timelines for completion, and regulatory submission dates for GSK's candidate are not yet fully specified in the available headlines. Analysts and industry observers are closely monitoring how this dual-target approach compares against existing market options and established regulatory precedents. As the rollout of late-stage trials proceeds, future coverage is expected to track the progression of GSK's Phase 3 testing and any subsequent clinical readouts. Observers will also be watching for further market responses from competing biotechnology firms, as well as additional guidance from public health officials regarding the deployment and efficacy of next-generation mRNA influenza immunizations.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| BioPharm International | GSK Advances mRNA Flu Vaccine Candidate to Phase 3 After Positive Phase 2 Data | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxOaWxwNXQtSnBvblBQV1FFZzVXS3FjSF9jSS1USEVLOGY2ZmxzNlhDcGljckJKZFNYQi1VQWFlb3FhMHJfWHJla3NTOXFkSy1VMGlIQUxvVjh6S0RmMF8zVVhUa200R0lUNGtmNUlJYVQ4cWtUODlhQkpqcDR5SU1rSHBtS1g4SU1TZnd0cHNQS3Nkb0tsUUZpMlZSQmY4aFo3d2dnUHlWM2g2LWVtamRoZWhjaEliVkZwOEVsX1QwMmpJZw?oc=5) |
| pharma.economictimes.indiatimes.com | GSK to advance mRNA flu vaccine to late-stage trial | [Source Link](https://news.google.com/rss/articles/CBMixAFBVV95cUxNR2h6RFdud29ZWTMtamFOd3hoMzRzNHpjS3Y5OG54Qk90Rm9MQkp0MGF3Z0JlWmdIU01INUx5M1NPSmtPWllWcV9fSnhhdmVjWk1kUWtjRUxhck11T0dudy1uSUN3bF9LbDQ2aHh3bThoVkF1QzZwMS1aWDkyMzJxWDVRX2Jid2dLR2R2cEs5NEpQUFp0UXZmUUtLRUtBX2xFYlZIdzRsbnlvZlZxVG5wMnJ6U1cycC1MM0MxOFg5SzNSMnhz0gHKAUFVX3lxTE56SkJBTGxsWTl5VEJjTnlJd0dBZG1KeU9GazNzR0RRZFVMMExqcEdWc2FkSnNGRlhuR3MtcTdBT0FKWHJINi11Zkg2RDEyLUhDVm54a1pMU2tGTm9HdHNlZDEwc3ZkaTFNam90c0NLT2FuUVVGdXI3alA2VzhPVnlhSmNvbFpNbk5FUXdiX2I) |
| 2 Minute Medicine | mFlusiva becomes the first mRNA influenza vaccine approved by the FDA | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxOd1ltYmZhcUxPb005TEEtaVdrUTM5ckxBanN2dGdGWVVIWkMwbS1nUzVJbUZsUUtjTTFrbXpiU2ZKQmhCSUJ5UEplaGFtaHVYRzVMN2JQX01ZZ254VjlEaVE4aUJoVlpWUUQ1TjRQUklBbmhlUGhWNGZPXzh1OEV2N0g5VHVuWXVBWmh4aE5UNU1oUDBjY1Y2VVJLd3EwRkc0dnV3RQ?oc=5) |
| finance.biggo.com | GSK Advances mRNA Flu Shot to Phase 3 After Beating Standard Vaccines in Mid-Stage Trial | [Source Link](https://news.google.com/rss/articles/CBMidkFVX3lxTE5jVXZxV21TLTBwQ2k2dS1fVUlxY2RiRV96U0hiU3RhTVo0Q3YtWS1Md0NocjlTRDIxRVJ0aEhsVGlzWFRvalJxSDlzNkYtelJoUk1CRXpHZGhVT3B4RWtfX2dseGNKUllEVTNBY3I5RFBBd21wOWc?oc=5) |
| 24/7 Wall St. | Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxOU1U4OV9SQ3RtLWktMVhHWnQyWmdFTXM0SC1paGQ5R05hX0Z3YV85Q05OWTBXYVBnVllnSzVRdy10eXltR1VUOGs5TEFzTnlLT3NXSWRKNnJjN3VuSWtRT2ZEM0tIR2s4dXk2Tk1qYlE2WEhmZ1lVa2VlWjNqeUJ1akc5RS1UUGQzckdBREE2NkxUc3Z5ZndkckhLNlJBdVphUHVsRnEzdVdiSHZPWmpHNldPWGc?oc=5) |
| Seeking Alpha | GSK: Still One Of My Top Healthcare Picks | [Source Link](https://news.google.com/rss/articles/CBMiiAFBVV95cUxPM0dXNllEQmQxRGNNclE0RDBxakpiX3hFcGVseHZHTVNmOW8ybkM2VmVRaTZtZmxoU2N4bGlKS0R2ZTZ0eDRIRVBYNmgxb08zZUtMeFRRQVludWR4bmQ0Uk9zNTExMzgxM2dQbWNVUmYwNVAwN19IWVZ0ZHNycXdwNzl3YkFDaWpr?oc=5) |
| Westlaw Today | GSK to advance mRNA flu vaccine to late-stage trial - Business Information & News - FE | [Source Link](https://news.google.com/rss/articles/CBMi3AFBVV95cUxOY3ZrWGdsSmZTY2ExM2hhSV8tR2pBX0lKeW5VeEttNnEyQk1hcmZ6QXpZWHRjWDlIVGlrV3FmMDdOUjZMejMzQWhkMmtFWTFrb1pVaHl1em9mdTVjUDNwbEJYaEcybG9BaHR1MXpYYllwejZxSHBaSVZqdlhtRkNaOEhldWNKUlV6SVU0SlMzblF5ZDdxckpKeXBMRUVyQnphb3J4ck1TSWx4NW51eFEyZ1pnb2ItLTFoYWdWQTM3ZF9yZmJyU2lDdWJqQTVsRDlDSVE3cjhkRm1Scm9Z?oc=5) |
| Endpoints News | GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxOLVdJVF9ONW9POVBKaXMzN3VRczlJWl90NG1HRWJzWk5IVmYzd0M1VW1MSWZyS2NQUzM1VHYzT25vendya2FMQTk2bnpZX0dfbkJubTNkLTlCMFpfaWJVY002b3pSSTVQWEpta1FGWURKRVRWZEFYSjRSNUU2OHBOUFI1ZkFKQXljUERSLTUzaWphZDV4YWVMNQ?oc=5) |
| AL.com | Big change for this year’s flu shot: When is the best time to get vaccinated? | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxOUG9iT0NNZnFZWTBiMDdEOEoyTXNkaVRBTVBTUjJGUC1FTDhDMlJaMDN4TENTcWRtd29PTm5uMzNzSXlYa1lTaVhDenNRaVVTMkdIMDQ2ZWxQSFEzRHNwSXEtVWxkTVRQQkd4S0tMRHRMX1I5TU03MTVESUhFc2JxX3NwTUVJakpSQjg5RTBoX2pVNVhhSk95dHl3NzU4THpVMXhxRTF5M1MtS19feHRHdtIBxAFBVV95cUxNYWNaZGIxdy1UQVVDNDItdERCSnJMM20tS1lISGpTcFpCZk5GLTZZVTc4T3VMSWt6NEVIT1BsUS1pQUdrNzhjWjJLQlVxWDdmZWtQdTdDSHR3emVZLTR6eDRNeEdyNDc2S25BdU5SX2ROazlGMEhCcVNpdUJhSWNEQjIwUng3eTJvV2U3enRyQk82RHpOLVJFSkVoRnYzbHYyZkx) |
| pharmaphorum | GSK pushes 'next-generation' mRNA flu shot into phase 3 | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxQV1RVU0N6MWZhVDFKMENNUk44TnAzSmNMTHhpU1ctaEdOcFUtb0lDZnNiaGU3R2lTQmVSR2V3SkY2TVJQSTk2WFRMNTB4NXhMTEMtRlNpcUNGWVRuTTJNVVpmcF9NM3JSTnlyMTQzVGQzTlQzOWgyVl9xQ2xfQ2VKRkVzNGQ?oc=5) |
| FirstWord Pharma | GSK takes dual-target mRNA flu shot to Phase III | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFA3WmstQlE2cHFRNHkxc0E5S0hfS1hyRTlLTEw5Nmc1NVJFLXpXUGc4dk9VeEhqWWI1ek9fUURJQnNoRlFVRXlCcWZGZWZwMTI2QllJ?oc=5) |
| Connecticut Public | New flu shot could give older adults better protection, CT health official says | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxQV3p6WVE2aFVNNmFFS1VmNUZZRENJWnhMRFpubUFfbFZRSzNMMHFkQ01nWW1rakRhZWR2b2M4enljWjdheEFEU0hRcTU3dWhBNEs2Q1g0cWRpcG1YTURYRS1HVThLN1Z2YmQ2a0JteER3cG4wSzJzT3JCdktSbHB5MWg5emp3bUdrX0dZNzFfSV9GV0xVdWpHc3RCRDFnRGZ0Slh6YmhHdHRPcjZRVUpIUGdacUtVWjJsR1dj?oc=5) |
| Yahoo | Big Change for This Year's Flu Shot: When Is the Best Time to Get Vaccinated? | [Source Link](https://news.google.com/rss/articles/CBMif0FVX3lxTE0zUEV4YnJPRHlGaTY2NldDQ2piY2xpVDIyZHk5dHU0RkNZejh2aEVwT1BBOWtMcEZNM1YxM2Z4M2FTX3dkakxXOXMzZ0VzbzJDc3NmMmd2M3AzYVlkWU81QTl0QUxXYmVOTkRmZTMtSzVyYmFubkhqbXVmbnFZMUE?oc=5) |
| BioSpace | GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality | [Source Link](https://news.google.com/rss/articles/CBMiyAFBVV95cUxPcXlwTjVtSnd1WWN3UjhFdUNMb0xNTFExQ0pLYTN0N2NrbDZOOVNpdVJIdzlSXzg0ZGRsNDRlVC1zNG4tS2xLZ1pUUFlOV0dPV0RqTGZaTGJPcTB3czNYNU5qdjlnelo5amJyVnBCY1JmOVh6Mm9FNm9xd3BTZTZzMEFyWXhDSHhaMTNfQmhvNWF4RTIyOG1pSUJfald5bHkydVRpZkZhdUU5bUx1Sm1QUEdvbW5Wa3R3Mm5fcl9BTnJlUTBtTVRCaA?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-01/gsk-catches-phase-3-fever-after-mrna-flu-vaccine-beats-standard-shots*